ArticleFrontiers in cellular and infection microbiology2023
Isolation and characterization of three novel lytic phages against K54 serotype carbapenem-resistant hypervirulent
Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 34 citations in OpenAlex.
- Phage anti-defense genes targeting NADVirulence · 2026Article
- Genomic and phenotypic characterization of Klebsiella pneumoniae phage KP Ø1: a novel lytic Slopekvirus targeting uropathogenic multidrug-resistant Klebsiella pneumoniae.Scientific reports · 2026Article
- Characterization and comparative genomic analysis of a novel bacteriophage against an extremely drug-resistantMicrobiology spectrum · 2026Article
- Systematic evaluation of phage cocktail-ciprofloxacin combination therapy against multidrug-resistantMicrobiology spectrum · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation, characterization, and therapeutic assessment of novel phage vB_LSKP32 targeting KL64-type carbapenem-resistant Klebsiella pneumoniae.Archives of virology · 2026Article
- Isolation and characterization of lytic bacteriophages with therapeutic potential against multidrug resistant Klebsiella pneumoniae from Ethiopia.Scientific reports · 2026Article
- Characterization of the bacteriophage vB_KpnP_Henu1_3 lytic for K1Microbiology spectrum · 2026Article
- Bacteriophage Therapy AgainstMicroorganisms · 2026Review
- Hypervirulent and Drug-ResistantInternational journal of general medicine · 2026Review
- A novel bacteriophage capable of efficiently lysing multi-drug-resistantFrontiers in microbiology · 2026Article
- Evolutionary Origins and Virulence Determinants of ST25 HypervirulentTransboundary and emerging diseases · 2026Article
- A lytic bacteriophage vB_KpnP-6K2 inhibits ST11-KL64Frontiers in cellular and infection microbiology · 2026Article
- Characterization and genomic analysis of DSF2: a novel lytic phage infecting multidrug-resistantFrontiers in microbiology · 2026Article
- Characterization and genome analysis of the Klebsiella webervirus vB_KpnS_2146-302.Archives of virology · 2025Article
- Isolation and characterization of a novel phage targeting Klebsiella pneumoniae K2 capsular type.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Identification and preclinical efficacy evaluation of two lytic bacteriophages targeting highly virulent and multidrug-resistant Klebsiella pneumoniae.Annals of clinical microbiology and antimicrobials · 2025Article
- Isolation and Characterization of Lytic Bacteriophages against Antibiotic-ResistantArchives of Razi Institute · 2025Article
- Characterization and Therapeutic Potential of Three Depolymerases Against K54 Capsular-TypeMicroorganisms · 2025Article
- Genomic analysis and therapeutic efficacy evaluation of bacteriophage PK2420 for pneumonia caused by hypervirulentmSystems · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of carbapenem-resistant hypervirulent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.